Emyria Recruits 31 Therapists to Meet Growing Patient Demand
Released
Released
Announcement PDF
Emyria ASX Announcement | 19 November 2026 1
ASX RELEASE.
19 November 2026
EMYRIA RECRUITS 31 THERAPISTS TO MEET GROWING
PATIENT DEMAND
Recruitment designed to meet expected growth in the number of patients treated
across Emyria’s national Empax network in 2027.
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in delivering evidence-
based intensive mental-health care, has recruited 31 additional therapists to support increased
patient treatment capacity and revenue-generating clinical activity across its national Empax
network in preparation for CY27.
The recruitment marks a significant milestone as Emyria moves from establishing its national
clinical infrastructure to scaling patient treatment volumes across its network.
Emyria treats people with post-traumatic stress disorder (PTSD) and treatment-resistant
depression (TRD) who have not improved with standard care. Each treatment needs trained
therapists to be with the patient for multi hour sessions. The number of trained therapists
therefore sets the number of patients that Emyria can treat.
The 31 therapists will commence specialised training on 27 November 2026, with progressive
onboarding into clinical operations expected from CYQ1 2027, subject to completion of the
training and supervised onboarding required to maintain clinical care standards.
Of the 31 recruits, 18 meet the Therapeutic Goods Administration (TGA) Lead Therapist
eligibility criteria and 10 are psychologists who will support Veteran treatments funded by the
Department of Veterans' Affairs (DVA), expanding Emyria's workforce capability to meet DVA
requirements and accommodate anticipated growth in government-funded treatment
volumes.
Training will be conducted in Perth. The cohort comprises 22 therapists from Perth, six from
Brisbane and three from Sydney. This will bring total trained therapists numbers in excess of
1501,2
.
• 31 additional therapists recruited – Specialised inhouse training commences 27
November 2026, to meet expected growth in the number of patients treated in 2027.
• 18 therapists meet TGA Lead Therapist eligibility criteria – Expanding the pool of
specialised clinicians required to support increased treatment volumes.
• Includes 10 psychologists – To meet DVA specific therapist requirements and support
anticipated progress in DVA-funded Veteran treatments during 2027.
• Existing clinics ready to treat more patients – Therapists allocated across Perth,
Brisbane and Sydney, with onboarding commencing CYQ1 2027. Higher utilisation of
existing clinics sits alongside continued network growth.
ASX RELEASE.
Emyria ASX Announcement | 19 November 2026 2
Preparing to Treat More Patients in 2027
Emyria has invested several years in establishing the specialised clinical infrastructure,
workforce training capabilities and treatment protocols required to deliver evidence-based
complex mental health treatments in real-world clinical settings.
With its national Empax network established across key Australian markets, the Company
expects the number of patients treated to increase in 2027. Improved utilisation of existing
clinics will complement continued network growth.
Therapist availability is a key determinant of treatment capacity. Emyria has 18 treatment beds
across five sites3
. Therapist numbers, not beds, limit the number of treatments today. More
therapists allows Emyria to treat more patients in these beds without new facility
commitments. The recruitment of 31 additional therapists is designed to accommodate this
expected growth in 2027, increasing utilisation of established infrastructure as clinicians
complete training and supervised onboarding.
The expanded workforce is expected to support increased treatment capacity and associated
revenue-generating opportunities across three established areas of Emyria's clinical delivery
model:
• Reimbursed patient treatments – Increasing the specialised clinical workforce
available to deliver Emyria’s PTSD and TRD programs across the national Empax
network, so that more patients can be treated through established reimbursement
pathways.
• DVA-funded Veteran treatments – Expanding the pool of psychologists available to
meet DVA workforce requirements and support anticipated growth in government-
funded treatment volumes for eligible Australian Veterans.
• Pharmaceutical-sponsored clinical trials – Strengthening the clinical workforce
available to support international pharmaceutical partnerships and sponsor-funded
research programs delivered through Emyria's Empax network.
This workforce expansion supports Emyria's strategy to increase patient treatment volumes
through 2027 while maintaining the clinical standards, patient safety and treatment
outcomes underpinning our care models.
Greg Hutchinson, Emyria Executive Chair, commented:
“Emyria has spent several years establishing the clinical infrastructure, specialist workforce
and treatment protocols required to deliver our PTSD and TRD programs at scale. With a
national network now established, our priority for 2027 is clear: make our treatments as
accessible as possible to those across the country suffering these often otherwise intractable
illnesses.
The recruitment of 31 additional therapists is an important step towards unlocking greater
treatment capacity across our existing Empax clinics. Every therapist who joins us lets us treat
more patients to the same clinical standard. Importantly, the inclusion of 10 psychologists to
support DVA-funded Veteran treatments strengthens our ability to respond to anticipated
growth in government-funded patient care.
We are now focused on translating our investment in clinical infrastructure into increased
patient treatments and, with that, increased commercial activity and revenue. Expanding
ASX RELEASE.
Emyria ASX Announcement | 19 November 2026 3
our specialised workforce is central to that strategy, supporting reimbursed patient care,
Veteran treatments and growing opportunities with international pharmaceutical partners.”
References
1) See ASX announcement 20 August 2026
2) See ASX June quarterly activities report 29 July 2026
3) See ASX announcement 29 September 2026
This release has been approved by the Board of Emyria.
For further information, investment opportunities, or more about Emyria’s approach to
mental health treatment, please contact:
Greg Hutchinson Executive Chair
1300 153 355 | investors@emyria.com
ASX RELEASE.
Emyria ASX Announcement | 19 November 2026 4
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about
future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and
other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including: the Company’s ability to
successfully develop its product candidates and timely complete its planned clinical programs and the
Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking
statements included in this press release represents the Company’s views as of the date hereof. The Company
anticipates that subsequent events and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date hereof.
Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin
All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess
the suitability of a new medication against a patient’s individual circumstances and medical history before
proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic
attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include
involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint
stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate.
There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are
unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while
appropriately managed in a controlled environment with direct medical supervision. The risk profile of the
MDMA inspired compounds is currently unknown.
The availability of these products is subject to the safety and efficacy of the products being tested through
clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the
products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD.
There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that
the TGA has evaluated for quality, safety and efficacy.
Emyria Limited develops and delivers new treatments for mental health and select neurological
conditions through an integrated model of direct clinical services and treatment development:
Emyria Healthcare: Evidence-based treatment for patients not finding relief
from conventional care while also helping evaluate emerging new therapies like
assisted therapy for PTSD and assisted therapy for treatment-resistant depression.
Emyria Data: Robust and ethically sourced Real-World Data gathered with patients
to improve Emyria’s unique therapy and drug development programs.
Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental
health and select neurological diseases.
EMYRIA’S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria’s announcements and
updates by asking questions and comments, which our team can respond
to where possible.
generates
informs
Share your feedback
Discover